|Positive WB detected in
|A431 cells, MDA-MB-453s cells, HeLa cells
|Positive IHC detected in
|human colon cancer tissue, human ovary tumor tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Positive IF detected in
|Western Blot (WB)
|WB : 1:1000-1:4000
|IHC : 1:50-1:500
|IF : 1:50-1:500
|It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
|Sample-dependent, check data in validation data gallery
26689-1-AP targets CYR61/CCN1 in WB, IHC, IF, ELISA applications and shows reactivity with human samples.
|human, mouse, rat
|Host / Isotype
|Rabbit / IgG
|CYR61/CCN1 fusion protein Ag25129
|cysteine-rich, angiogenic inducer, 61
|Calculated molecular weight
|Observed molecular weight
|GenBank accession number
|Gene ID (NCBI)
|Antigen affinity purification
|PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
|Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.
CYR61 is a member of the CYR61/CTGF/NOV (CCN) protein family. CYR61 participated in cell mitogenesis, cellular adhesion, migration, differentiation, angiogenesis, and survival. Cyr61 is especially associated with diseases related to chronic inﬂammation, including RA, Crohn's disease and ulcerative colitis. CYR61 may serve essential roles as either an oncogene or a tumor suppressor, depending on the cancer cell type. CYR61 also induces angiogenesis, which supplies oxygen and nutrients to tumors during growth. CYR61 can also play a role in the proliferation, invasion, survival, and metastasis of cancer cells.
A translational program that suppresses metabolism to shield the genome.
ACS Appl Mater Interfaces
A Novel Electrochemiluminescent Immunoassay Based on Target Transformation Assisted with Catalyzed Hairpin Assembly Amplification for the Ultrasensitive Bioassay.
Mol Ther Nucleic Acids
The RNA binding protein QKI5 suppresses ovarian cancer via downregulating transcriptional coactivator TAZ.
Cell Death Dis
EGFR-PI3K-PDK1 pathway regulates YAP signaling in hepatocellular carcinoma: the mechanism and its implications in targeted therapy.
WISP2/CCN5 Suppresses Vasculogenic Mimicry through Inhibition of YAP/TAZ Signaling in Breast Cancer Cells.
Hum Mol Genet
Abnormal activation of yap/Taz contributes to the pathogenesis of tuberous sclerosis complex.